Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
30.34
+0.61 (2.05%)
Oct 9, 2026, 10:14 AM EDT - Market open
Vera Therapeutics Employees
Vera Therapeutics had 361 employees as of June 30, 2026. The number of employees increased by 169 or 88.02% compared to the same quarter last year. That makes Vera Therapeutics the 22,540th largest employer in the world and 2,939th in the United States.
Employees
361
Change
169
Growth
88.02%
Revenue / Employee
n/a
Profits / Employee
-$1,113,283
Market Cap
2.19B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 361 | 169 | 88.02% |
| Mar 31, 2026 | 339 | 187 | 123.03% |
| Dec 31, 2025 | 249 | 137 | 122.32% |
| Sep 30, 2025 | 224 | 142 | 173.17% |
| Jun 30, 2025 | 192 | 120 | 166.67% |
| Mar 31, 2025 | 152 | 97 | 176.36% |
| Dec 31, 2024 | 112 | 61 | 119.61% |
| Sep 30, 2024 | 82 | 33 | 67.35% |
| Jun 30, 2024 | 72 | 23 | 46.94% |
| Mar 31, 2024 | 55 | 9 | 19.57% |
| Dec 31, 2023 | 51 | 5 | 10.87% |
| Sep 30, 2023 | 49 | 8 | 19.51% |
| Jun 30, 2023 | 49 | 20 | 68.97% |
| Mar 31, 2023 | 46 | 28 | 155.56% |
| Dec 31, 2022 | 46 | 29 | 170.59% |
| Sep 30, 2022 | 41 | 26 | 173.33% |
| Jun 30, 2022 | 29 | 16 | 123.08% |
| Mar 31, 2022 | 18 | 6 | 50.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| Recursion Pharmaceuticals | 600 |
| Vericel | 398 |
| Nurix Therapeutics | 317 |
| Harmony Biosciences Holdings | 293 |
| Viridian Therapeutics | 252 |
| Immunome | 247 |
| Disc Medicine | 165 |
VERA News
- 3 hours ago - Vera Therapeutics price target lowered to $60 from $66 at BofA - TheFly
- 6 days ago - Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Vera Therapeutics announces ORIGIN 3 final efficacy analysis of Trutakna - TheFly
- 7 days ago - Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 - GlobeNewsWire
- 23 days ago - Vera Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 23 days ago - Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results - Barrons
- 23 days ago - Why is Vera Therapeutics stock reversing its premarket gains? - Invezz
- 24 days ago - Vera Therapeutics ORIGIN 3 study results positive, says Raymond James - TheFly